

# SAFETY DATA SHEET

## 1. Identification of the substance or preparation and the company/ undertaking

### 1.1 Product Identifier

**Product Name:** Mast Actinomycete Selectatab™

**Product Code:** MS25

### 1.2 Relevant identified uses of the substance or mixture and uses advised against

**Recommended uses:** *In vitro* diagnostic product; Laboratory chemical

**Uses advised against:** No information available

### 1.3 Details of supplier of the product and safety data sheet

**Manufacturer/supplier:** Mast Group Ltd., Mast House,  
Derby Road,  
Bootle,  
Merseyside,  
UK.  
L20 1EA  
Telephone: +44 (0) 151 933 7277  
Email: uksales@mastgrp.com  
Web: www.mastgrp.com

Feldstraße 20  
23858 Reinfeld  
Germany  
Telephone: +49 4533 20 07 34  
Email: mast@mast-diagnostics.de  
Web: www.mast-group.com

### 1.4 Emergency Contact information

UK contact: Telephone: +44 (0) 151 933 7277 (8am - 5pm GMT Monday to Friday)

EU contact: Telephone: +49 4533 20 07 34 (7am - 4pm GMT Monday to Friday)

## 2. Hazards identification

### 2.1 Classification of the substance or mixture

**CLP Classification – Regulation (EC) No. 1272/2008:**

**Physical hazards:** Based on available data, there are no physical hazards

**Health hazards:** Skin sensitisation Cat. 1: respiratory sensitisation Cat. 1.

**Environmental hazards:** Based on available data, there are no environmental hazards

### 2.2 Label elements

**Pictogram:**



**Signal word:** Danger

**Hazard statements:** H317 - May cause an allergic skin reaction  
H334 - May cause allergy or asthma symptoms or breathing difficulties if inhaled

**Precautionary statements:** P261 - Avoid breathing dust.  
P280 - Wear protective gloves.  
P342 + P311 - If experiencing respiratory symptoms: Call a Poison Centre or doctor/ physician.

### 2.3 Other hazards

No information available

# SAFETY DATA SHEET



In accordance with Regulation (EC) No 2020/878  
Revision date: 02/11/2022  
Version number: 04

## 3. Composition/information on ingredients

**Composition:** A multi-component freeze-dried tablet containing metronidazole and nalidixic acid in an inert carrier.

### Hazardous ingredients:

Component	CAS-No.	EC-No.	Concentration	CLP Classification – 1272/2008/EC	Classification to – 67/548/EEC
Metronidazole	443-48-1	207-136-1	<1%	Carcinogenicity Cat. 2. H351 - Suspected of causing cancer	Xn, harmful. R40 - Limited evidence of a carcinogenic effect.
Nalidixic acid	3374-05-8	222-159-7	<6%	Skin sensitisation Cat. 1: respiratory sensitisation Cat. 1: Acute toxicity Oral Cat. 4. H302 - Harmful if swallowed. H317 - May cause an allergic skin reaction H334 - May cause allergy or asthma symptoms or breathing difficulties if inhaled.	Xn - Harmful R42/43 - may cause sensitisation by inhalation and skin contact

## 4. First-aid measures

### 4.1 Description of First Aid measures

General advice: Consult a physician. Show this safety data sheet to the doctor in attendance.

Eye contact: Rinse thoroughly with plenty of water for 10 to 15 minutes, also under the eyelids. Obtain medical attention if irritation persists.

Skin Contact: Wash off skin thoroughly with soap and plenty of water. Obtain medical attention if irritation persists.

Ingestion: Rinse mouth out with plenty of water. Obtain medical attention if symptoms occur.

Inhalation: Move person to fresh air. Obtain medical attention immediately if symptoms occur.

### 4.2 Most important symptoms and effects, both acute and delayed

No information available.

### 4.3 Indicate any immediate medical attention and special treatment needed

No information available.

## 5. Fire fighting measures

### 5.1 Extinguishing medium

Suitable extinguishing media: Use water spray, CO<sub>2</sub>, foam or dry powder as the extinguisher medium.

Extinguishing media which must not be used for safety reasons: No information available

### 5.2 Special hazards arising from the substance or mixture

Combustible material. Thermal decomposition may lead to release of irritating gases and vapours.

### 5.3 Advice for firefighters

Wear suitable self contained breathing apparatus for fire fighting if necessary.

### 5.4 Additional information

No data available.

# SAFETY DATA SHEET



In accordance with Regulation (EC) No 2020/878  
Revision date: 02/11/2022  
Version number: 04

## 6. Accidental release measures

### 6.1 Personal precautions, protective equipment and emergency procedures

Ensure adequate ventilation. Wear appropriate protective equipment. Avoid dust formation.

### 6.2 Environmental precautions

Should not be released into the environment.

### 6.3 Methods and materials for contamination and cleaning up

Sweep up or vacuum up spillage in suitable container for disposal. Avoid dust formation.

### 6.4 Further information

No data available.

## 7. Handling and storage

### 7.1 Precautions for safe handling

Avoid contact with eyes, skin and clothing. Avoid ingestion and inhalation. Avoid dust formation.

### 7.2 Conditions for safe storage, including any incompatibilities

Store at 2 to 8°C. Keep tightly closed in the container provided. Protect from direct sunlight and moisture.

### 7.3 Specific end use(s)

This product is for laboratory use only and should only be used by suitably trained laboratory personnel.

## 8. Exposure controls and personal protection

### 8.1 Control parameters

Components with workspace control parameters: Contains no substance with occupational exposure limits.

### 8.2 Exposure controls

Engineering controls: No engineering protection required.

Personal protective measures: Body protection: Wear standard microbiology laboratory coat.

Eye/face protection: Safety glasses with side shields conforming to EN 166.

Skin and hand protection: Handle with suitable gloves conforming to EN 374.

Respiratory protection: Wear a face mask to EN149 FFP2S or use a ventilated extraction weighing cabinet.

General hygiene measures: Handle in accordance with good laboratory practice.  
Wash hands before breaks and at the end of the working day.

# SAFETY DATA SHEET



In accordance with Regulation (EC) No 2020/878  
Revision date: 02/11/2022  
Version number: 04

## 9. Physical and Chemical properties

### 9.1 Information on basic physical and chemical properties

Physical state:	Lyophilised tablet.
Colour:	White to off-white colour.
Odour:	Odourless.
Melting point/freezing point:	No data available.
Initial boiling point/range:	No data available.
Flammability:	No data available.
Lower and upper explosion limit:	No data available.
Flash point:	No data available.
Auto-ignition temperature:	No data available.
Decomposition temperature:	No data available.
pH	No data available.
Kinetic viscosity:	No data available.
Solubility in water/other solvents:	No data available.
Partition coefficient (n-octanol/water):	No data available.
Vapour pressure:	No data available.
Density/Relative density:	No data available.
Relative vapour density:	No data available.
Decomposition temperature	No data available.
Particle characteristics:	No data available.

### 9.2 Other information

No data available.

## 10. Stability and reactivity

### 10.1 Reactivity

No known on information available.

### 10.2 Chemical stability

Stable under normal conditions.

### 10.3 Possibility of hazardous reactions

No data available.

### 10.4 Conditions to avoid

Hygroscopic. Avoid exposure to sunlight.

### 10.5 Incompatible materials

None known.

### 10.6 Hazardous decomposition products

None under normal use conditions.

# SAFETY DATA SHEET



In accordance with Regulation (EC) No 2020/878  
Revision date: 02/11/2022  
Version number: 04

## 11. Toxicological information

### 11.1 Information on toxicological effects

Overall product information: This product does not present an acute toxicity based on known or supplied information.

### 11.2 Toxicological data for the components

Acute toxicity: For metronidazole: LD<sub>50</sub> Oral - rat - 3,000 mg/kg  
Remarks: Behavioural: Somnolence. Cyanosis Nutritional and Gross  
Metabolic: Changes in: Body temperature decrease.  
For further information see RTECS: NI5600000

For nalidixic acid: No data available. For further information see RTECS: QN2885500

Skin corrosion/irritation: No data available.

Serious eye damage/ eye irritation: No data available.

Respiratory or skin sensitisation: May cause allergic respiratory and skin reactions.

Germ cell mutagenicity: No data available.

Carcinogenicity: This product is or contains a component that has been reported to be possibly carcinogenic based on its IARC, ACGIH, NTP, or EPA classification.  
Limited evidence of carcinogenicity in animal studies No data available. IARC: 2B - Group 2B:  
Possibly carcinogenic to humans (Metronidazole)

Reproductive toxicity: No data available.

Specific target organ toxicity – single exposure: No data available.

Specific target organ toxicity – repeated exposure: No data available.

Aspiration hazard: No data available.

Potential health effects: Inhalation - May be harmful if inhaled. May cause respiratory tract irritation.  
Ingestion - May be harmful if swallowed.  
Skin - May be harmful if absorbed through skin. May cause skin irritation.  
Eyes - May cause eye irritation.

### 11.2 Toxicological data for the components

Assess endocrine disrupting properties for human health. This product does not contain any known or suspected endocrine disruptors.

## 12. Ecological information

### 12.1 Toxicity

Toxicity to fish - LC50 - Oncorhynchus mykiss (rainbow trout) - > 100 mg/l - 96 h

Mortality NOEC - Danio rerio (zebra fish) - 500 mg/l - 96 h

Toxicity to daphnia and other aquatic invertebrates EC50 - Daphnia magna (Water flea) - > 1,000 mg/l - 48 h

### 12.2 Persistence and degradability

No data available.

### 12.3 Bioaccumulative potential

No data available.

### 12.4 Mobility in soil

No data available.

### 12.5 Results of PBT and vPvB assessment

PBT/vPvB assessment not available as chemical safety assessment not required/not conducted.

# SAFETY DATA SHEET



In accordance with Regulation (EC) No 2020/878  
Revision date: 02/11/2022  
Version number: 04

## **12.6 Endocrine disrupting properties: requiring you to give product information on adverse effects on the environment caused by endocrine-disrupting properties**

This product does not contain any known or suspected endocrine disruptors.

## **12.7 Other adverse effects**

No data available

### **1. Disposal considerations**

Disposal considerations: Dispose of in accordance with local and national regulations.  
Dispose of all used contaminated waste, e.g. used plates, according to local microbiological rules.

### **2. Transport information**

#### **2.1 UN Number**

ADR/RID: IMDG: IATA: Not dangerous for shipping

#### **2.2 UN proper shipping name**

ADR/RID: IMDG: IATA: Not dangerous for shipping

#### **2.3 Transport hazard class(es)**

ADR/RID: IMDG: IATA: Not dangerous for shipping

#### **2.4 Packaging group**

ADR/RID: IMDG: IATA: Not dangerous for shipping

#### **2.5 Environmental hazards**

ADR/RID: IMDG: IATA: None known.

#### **2.6 Special precautions for user**

No data available

#### **2.7 Maritime transport in bulk according to IMO instruments**

No data available

### **3. Regulatory information**

#### **3.1 Safety, health and environmental regulations/legislation specific for the substance or mixture**

No data available.

#### **3.2 Chemical safety assessment**

Chemical safety assessment reports are not required for mixtures/IVD products.

### **4. Other information**

Original origination date: 27/11/1995

Reason for change to document: Updated in accordance with Regulation (EC) No 2020/878

The above information is believed to be correct but does not purport to be all inclusive and shall be used as a guide only. The information in this document is based on the present state of our knowledge and is applicable to the product with regard to appropriate safety precautions. It does not represent any guarantee of the properties of the product and is designed only as a guide for safe handling, use, processing, storage, transportation, disposal and release and is not to be considered a warranty or quality specification. Mast Group Ltd. shall not be held liable for any damage resulting from handling or from contact with the above product. See our website at [www.mast.grp.com](http://www.mast.grp.com) and/or the reverse side of our invoice for additional terms and conditions of sale.

# SAFETY DATA SHEET



In accordance with Regulation (EC) No 2020/878  
Revision date: 02/11/2022  
Version number: 04